Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.

Objectives: Biosimilars improve patient access by providing cost-effective treatment options. This study assessed the potential savings and expanded patient access with increased use of two biosimilar disease modifying anti-rheumatic drugs (DMARDs): a) approved adalimumab biosimilars and b) the first tocilizumab biosimilar, representing an established biosimilar field and a recent biosimilar entrant in France, Germany, Italy, Spain, and the United Kingdom (UK).Methods: Separate ex-ante analyses were conducted for each country, parameterized using country-specific list prices, unit volumes annually, and market shares for each therapy. Discounting scenarios of 10%, 20%, and 30% were tested for tocilizumab. Outputs included direct cost-savings associated with drug acquisition or the incremental number of patients that could be treated if savings were redirected. Two biosimilar conversion scenarios were tested.Results: Savings associated with a 100% conversion to adalimumab biosimilar ranged from €10.5 to €187 million (UK and Germany, respectively), or an additional 1,096 to 19,454 patients that could be treated using the cost-savings. Introduction of a tocilizumab biosimilar provided savings up to €29.3 million in the most conservative scenario. Exclusive use of tocilizumab biosimilars (at a 30% discount) could increase savings to €28.8 to €113 million or expand access to an additional 43% of existing tocilizumab users across countries.Conclusion: This study demonstrates the benefits that can be realized through increased biosimilar adoption, not only in an untapped tocilizumab market, but also through incremental increases in well-established markets such as adalimumab. As healthcare budgets continue to face downwards pressure globally, strategies to increase biosimilar market share could prove useful to help manage financial constraints.

The Promise of Soft-Matter-Enabled Quantum Materials.

The field of quantum materials has experienced rapid growth over the past decade, driven by exciting new discoveries with immense transformative potential. Traditional synthetic methods to quantum materials have, however, limited the exploration of architectural control beyond the atomic scale. By contrast, soft matter self-assembly can be used to tailor material structure over a large range of length scales, with a vast array of possible form factors, promising emerging quantum material properties at the mesoscale. This review explores opportunities for soft matter science to impact the synthesis of quantum materials with advanced properties. Existing work at the interface of these two fields is highlighted, and perspectives are provided on possible future directions by discussing the potential benefits and challenges which can arise from their bridging.

Frequency-selective propagation of localized spoof surface plasmons in a graded plasmonic resonator chain.

Localized spoof surface plasmon polaritons (spoof-SPPs) in a graded spoof-plasmonic resonator chain with linearly increasing spacing are experimentally investigated at microwave frequencies. Transmission measurements and direct near-field mappings on this graded chain show that the propagation of localized spoof-SPPs can be cutoff at different positions along the graded chain under different frequencies due to the graded coupling between adjacent resonators. This mechanism can be used to guide localized spoof-SPPs in the graded chain to specific positions depending on the frequency and thereby implement a device that can work as a selective switch in integrated plasmonic circuits.